NEOPHORE
NeoPhore is a provider of novel small molecule therapies intended to treat cancer through stimulation of the immune system.The company's small molecule therapies target genetic mechanisms in order to create neoantigen which is known to stimulate the immune system and potentially be a weak spot in a tumor cell's defense mechanisms, enabling cancer patients to get treated and achieve improved clinical outcomes.
NEOPHORE
Industry:
Biotechnology Simulation Therapeutics Translation Service
Founded:
2017-11-01
Address:
Cambridge, Cambridgeshire, United Kingdom
Country:
United Kingdom
Website Url:
http://www.neophore.com
Total Employee:
1+
Status:
Active
Contact:
+44 (0)1223 804250
Email Addresses:
[email protected]
Total Funding:
25.07 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Analytics LetsEncrypt Google Universal Analytics Apache Mobile Non Scaleable Content Microsoft Exchange Online
Current Advisors List
Current Employees Featured
Founder
Investors List
2invest
2invest investment in Series B - NeoPhore
Astellas Venture Management
Astellas Venture Management investment in Series B - NeoPhore
3B Future Health Fund
3B Future Health Fund investment in Series B - NeoPhore
Claris Ventures
Claris Ventures investment in Series B - NeoPhore
Sixth Element Capital
Sixth Element Capital investment in Series B - NeoPhore
Innovate UK
Innovate UK investment in Grant - NeoPhore
Sixth Element Capital
Sixth Element Capital investment in Venture Round - NeoPhore
Official Site Inspections
http://www.neophore.com Semrush global rank: 5.48 M Semrush visits lastest month: 1.56 K
- Host name: kisscab2.miniserver.com
- IP address: 89.200.137.201
- Location: United Kingdom
- Latitude: 51.4964
- Longitude: -0.1224
- Timezone: Europe/London
More informations about "NeoPhore"
NeoPhore - Cancer Neoantigen Evolution | Neophore
Our approach targets the dynamics of cancer neoantigen evolution through the discovery and design of effective, well-tolerated medicines that will become a key part of the next-generation …See details»
About - NeoPhore
NeoPhore is pursuing novel and innovative approaches that build upon the well-established links between MMR function and clinical efficacy. Few mechanisms are as fundamental to cancer immunity, or are as well-proven by both pre …See details»
NeoPhore raises an additional £9.6m (USD $12.2m) Series B …
Feb 1, 2024 · NeoPhore is building a pipeline of small molecule drugs targeting novel proteins across the DNA mismatch repair ('MMR') pathway to generate next-generation immuno …See details»
NeoPhore Ltd - LinkedIn
Discovering drugs that create neoantigens | NeoPhore, UK is focused on the discovery and development of novel small molecule therapies to treat cancer through stimulation of the immune system.See details»
NeoPhore - Crunchbase Company Profile & Funding
NeoPhore is a provider of novel small molecule therapies intended to treat cancer through stimulation of the immune system. Cambridge , Cambridgeshire , United Kingdom 1-10See details»
NeoPhore Company Profile 2024: Valuation, Funding & Investors
NeoPhore was founded in 2017. Where is NeoPhore headquartered? NeoPhore is headquartered in Altrincham, United Kingdom. What is the size of NeoPhore? NeoPhore has 10 total …See details»
NeoPhore - Claris Ventures
NeoPhore is discovering medicines that stimulate neoantigen creation in cancer cells marking them for attack by a patient’s own immune system. NeoPhore’s drugs are designed to …See details»
NeoPhore - VentureRadar
Website: http://neophore.com Develops immuno-oncology therapeutics by targeting DNA mismatch repair pathway proteins. Conducts pre-clinical studies to improve cancer patient …See details»
NeoPhore completes extension to Series B financing to further …
CAMBRIDGE, England , Jan. 19, 2023 /PRNewswire/ -- NeoPhore Limited, a small molecule neoantigen immuno-oncology company, today announces the completion of its £21.5m (US …See details»
NeoPhore's Leadership Team - Team members and org chart
NeoPhore's Leadership Team includes Matthew Baker and 8 others.See details»
NeoPhore raises an additional £9.6m (USD $12.2m) Series B …
Feb 1, 2024 · NeoPhore is building a pipeline of small molecule drugs targeting novel proteins across the DNA mismatch repair ('MMR') pathway to generate next-generation immuno …See details»
NeoPhore Announces $21m Financing to Advance DNA Mismatch …
09 March 2021, Cambridge, UK – NeoPhore Limited, a small molecule neoantigen immuno-oncology company, today announces the close of a £15.2m (US $21m) Series B round. The …See details»
NeoPhore Announces £15.2m Financing to Advance DNA ... - PR …
CAMBRIDGE, England, March 9, 2021 /PRNewswire/ -- NeoPhore Limited, a small molecule neoantigen immuno-oncology company, today announces the close of a £15.2m (US $21m) …See details»
Matthew Baker - CEO at NeoPhore - The Org
Matthew has held entrepreneurial and leadership positions across the biotechnology industry including Chief Scientific Officer of Abzena plc and co-founder, Chief Scientific Officer of …See details»
NeoPhore adds $12.2m in Series B extension for immuno …
Feb 1, 2024 · NeoPhore is developing a pipeline of drugs targeting proteins along the DNA mismatch repair (MMR) pathway. Image credit: Shutterstock/Billion Photos. NeoPhore has …See details»
NeoPhore Announces £15.2m Financing to Advance DNA …
Mar 9, 2021 · Using these insights, NeoPhore aims to generate next-generation immuno-oncology therapeutics to improve clinical outcomes for cancer patients. NeoPhore was spun-out of the …See details»
NeoPhore closes oversubscribed Series B extension round with …
May 22, 2024 · NeoPhore Limited, a small molecule neoantigen immuno-oncology company, today announces that Bristol Myers Squibb (NYSE: BMY) has joined its oversubscribed Series …See details»
Neophore closed £15.2m series B round successfully and ... - o2h …
Cambridge, UK, July 05 2021: o2h discovery is delighted to announce that one of its collaborators, NeoPhore Limited, a small molecule neoantigen immuno-oncology company …See details»
NeoPhore Scientific Founders Publish Breakthrough Immuno …
Nov 29, 2017 · NeoPhore, based in Cambridge, UK is focused on the discovery and development of novel small molecule therapies to treat cancer through stimulation of the immune system. …See details»